• In May 2026, Precigen, Inc. reported first-quarter 2026 results showing revenue of US$23.25 million versus US$1.34 million a year earlier, with net loss narrowing to US$7.93 million from US$54.15 million and basic loss per share from continuing operations improving to US$0.02 from US$0.18.
• The results highlighted how the launch of PAPZIMEOS and continued development of PRGN-2009 in HPV-associated cancers are reshaping Precigen’s financial profile and therapeutic focus.
• We’ll now examine how PAPZIMEOS-driven revenue momentum reshapes Precigen’s existing investment narrative and its longer-term earnings assumptions.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Precigen Investment Narrative Recap

To own Precigen, you need to believe PAPZIMEOS can scale from a single adult RRP indication into a durable, cash-generating franchise while PRGN-2009 builds a second pillar in HPV-driven cancers. The Q1 2026 revenue jump to US$23.25 million and sharply lower net loss support the near term catalyst of PAPZIMEOS launch execution, but do not remove the key risk that slower-than-hoped patient uptake and pricing pressure could still stretch the path to cash flow breakeven.

Among recent announcements, the RRPF sponsored expert consensus paper in January 2026, which endorsed PAPZIMEOS as first line therapy for adults with RRP, looks especially relevant beside these results. That independent clinical backing, combined with early sales traction, speaks directly to the core catalyst of turning pent up demand in a previously underserved population into sustained product revenue, while also framing the risk that real world durability or safety data could still influence how widely physicians adopt the therapy.

Yet even with strong Q1 numbers and growing clinical endorsement, investors should be aware that the company’s reliance on a single approved indication means...

Precigen's narrative projects $299.5 million revenue and $118.4 million earnings by 2028. This requires 262.1% yearly revenue growth and a $544.3 million earnings increase from $-425.9 million today.

Uncover how Precigen's forecasts yield a $8.50 fair value, a 100% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community range from US$0.52 to US$43.95 per share, underlining how far apart individual views can be. When you set those side by side with the current focus on PAPZIMEOS uptake and the risk that slower patient pull through could still force extra financing, it becomes clear why exploring several alternative viewpoints on Precigen’s outlook is essential.

Explore 10 other fair value estimates on Precigen - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Precigen research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.